Tag Archives: Jim Birchenough

Wells Fargo Downgrades Immunomedics (IMMU) to Hold

Immunomedics (IMMU – Research Report) received a Hold rating from Wells Fargo analyst Jim Birchenough today. The company’s shares closed last Friday at $42.25, close to its 52-week high of $45.69. According to TipRanks.com, Birchenough is a 5-star analyst with

Wells Fargo Keeps Their Buy Rating on Immunomedics (IMMU)

In a report released today, Jim Birchenough from Wells Fargo maintained a Buy rating on Immunomedics (IMMU – Research Report). The company’s shares closed last Monday at $40.01. According to TipRanks.com, Birchenough is a 5-star analyst with an average return

Wells Fargo Reaffirms Their Buy Rating on Bluebird Bio (BLUE)

Wells Fargo analyst Jim Birchenough maintained a Buy rating on Bluebird Bio (BLUE – Research Report) today. The company’s shares closed last Monday at $45.74, close to its 52-week low of $38.95. According to TipRanks.com, Birchenough is a 5-star analyst

Principia Biopharma (PRNB) Gets a Buy Rating from Wells Fargo

In a report released yesterday, Jim Birchenough from Wells Fargo maintained a Buy rating on Principia Biopharma (PRNB – Research Report). The company’s shares closed last Monday at $69.01, close to its 52-week high of $69.38. According to TipRanks.com, Birchenough

Crispr Therapeutics AG (CRSP) Receives a Buy from Wells Fargo

Wells Fargo analyst Jim Birchenough maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) yesterday. The company’s shares closed last Monday at $72.37, close to its 52-week high of $74.00. According to TipRanks.com, Birchenough is a 5-star

Analysts Are Bullish on These Healthcare Stocks: Akcea Therapeutics (AKCA), Abbott Labs (ABT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akcea Therapeutics (AKCA – Research Report), Abbott Labs (ABT – Research Report) and Jazz Pharmaceuticals (JAZZ – Research Report) with bullish sentiments.